Understanding dystonia: diagnostic issues and how to overcome them

ABSTRACT

The diagnosis and treatment of dystonia are challenging. This is likely due to gaps in the complete understanding of its pathophysiology, lack of animal models for translational studies, absence of a consistent pathological substrate and highly variable phenotypes and genotypes. The aim of this review article is to provide an overview of the clinical, neurophysiological and genetic features of dystonia that can help in the identification of this movement disorder, as well as in the differential diagnosis of the main forms of genetic dystonia. The variation of penetrance, age of onset, and topographic distribution of the disease in carriers of the same genetic mutation indicates that other factors – either genetic or environmental – might be involved in the development of symptoms. The growing knowledge of cell dysfunction in mutants may give insights into more effective therapeutic targets.

RESUMO

O diagnóstico e o tratamento da distonia podem ser desafiadores. Isso se dá provavelmente a pouca compreensão da fisiopatologia, a falta de modelos animais para estudos translacionais, ausência de um substrato patológico consistente e genótipo e fenótipo altamente variáveis. O objetivo deste artigo de revisão é fornecer uma visão geral dos aspectos clínicos, neurofisiológicos e genéticos de distonia que podem ajudar na identificação deste distúrbio do movimento, bem como no diagnóstico diferencial das principais formas de distonia hereditária. Há uma ênfase particular na nova definição e classificação da Internacional das Distonias, bem como as recentes descobertas dos mecanismos moleculares subjacentes em algumas formas de distonia primária. A variação de penetrância, idade de início, e distribuição topográfica da doença em portadores da mesma mutação genética indica que outros fatores - genéticos ou ambientais podem estar envolvidos no desenvolvimento dos sintomas. O conhecimento crescente sobre a disfunção celular em mutantes pode gerar insights sobre alvos terapêuticos mais eficazes.

dystonia - apoptosis

distonia - apoptose

Publication History

Received: 16 May 2016

Accepted: 07 July 2016

Article published online:
06 September 2023

• References

• 1 Lanska DJ. Chapter 33: the history of movement disorders. Handb Clin Neurol. 2010;95:501-46. doi:10.1016/S0072-9752(08)02133-7
• 2 Munts AG, Koehler PJ. How psychogenic is dystonia? Views from past to present. Brain. 2010;133(5):1552-64. doi:10.1093/brain/awq050
• 3 Fahn S. Concept and classification of dystonia. Adv Neurol. 1988;50:1-8. doi:10.1212/WNL.50.5_Suppl_5.S1
• 4 Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet. 1997;17(1):40-8. doi:10.1038/ng0997-40
• 5 Broussolle E, Laurencin C, Bernard E, Thobois S, Danaila T, Krack P. Early ilustrations of geste antagoniste in cervical and generalized dystonia. Tremor Other Hyperkinet Mov (N Y) 2015;5:332-44. doi:10.7916/D8KD1X74
• 6 Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv Neurol. 2004:94:101-7.
• 7 Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-73. doi:10.1002/mds.25475
• 8 Albanese A, Lalli S. Is this dystonia? Mov Disord. 2009;24(12):1725-31. doi:10.1002/mds.22597
• 9 Loyola DP, Camargos S, Maia D, Cardoso F. Sensory tricks in focal dystonia and hemifacial spasm. Eur J Neurol. 2013;20(4):704-7. doi:10.1111/ene.12054
• 10 Sitburana O, Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009;15(10):758-61. doi:10.1016/j.parkreldis.2009.05.003
• 11 Hallett M. Pathophysiology of writer’s cramp. Hum Mov Sci. 2006;25(4-5):454-63. doi:10.1016/j.humov.2006.05.004
• 12 Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol. 2004;56(4):595-9. doi:10.1002/ana.20270
• 13 Cox BC, Cincotta M, Espay AJ. Mirror movements in movement disorders: a review. Tremor Other Hyperkinet Mov (NY). 2012;2. pii: tre-02-59-398-1. doi:10.7916/D8VQ31DZ
• 14 Castrioto A, Piscicelli C, Pérennou D, Krack P, Debû B. The pathogenesis of Pisa syndrome in Parkinson’s disease. Mov Disord. 2014;29(9):1100-7. doi:10.1002/mds.25925
• 15 Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 2011;10(6):538-49. doi:10.1016/S1474-4422(11)70067-9
• 16 Schrag A, Trimble M, Quinn N, Bhatia K. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain. 2004;127(10):2360–72. doi:10.1093/brain/awh262
• 17 Erro R, Rubio-Agusti I, Saifee TA, Cordivari C, Ganos C, Batla A et al. Rest and other types of tremor in adult-onset primary dystonia. J Neurol Neurosurg Psychiatry. 2014;85(9):965-8. doi:10.1136/jnnp-2013-305876
• 18 Agnew A, Frucht SJ, Louis ED. Supine head tremor: a clinical comparison of essential tremor and spasmodic torticollis patients. J Neurol Neurosurg Psychiatry. 2012;83(2):179-81. doi:10.1136/jnnp-2011-300823
• 19 Quinn NP, Schneider SA, Schwingenschuh P, Bhatia KP. Tremor: some controversial aspects. Mov Disord. 2011;26(1):18-23. doi: 0.1002/mds.23289
• 20 Mian OS, Schneider SA, Schwingenschuh P, Bhatia KP, Day BL. Gait in SWEDDs patients: comparison with Parkinson’s disease patients and healthy controls. Mov Disord. 2011;26(7):1266-73. doi:10.1002/mds.23684
• 21 Batla A, Erro R, Stamelou M, Schneider SA, Schwingenschuh P, Ganos C et al. Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord. 2014;29(14):1820-5. doi:10.1002/mds.26018
• 22 Peall KJ1, Smith DJ, Kurian MA, Wardle M, Waite AJ, Hedderly T et al. SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain. 2013;136(1):294-303. doi:10.1093/brain/aws308
• 23 Tricht MJ1, Dreissen YE, Cath D, Dijk JM, Contarino MF, Salm SM et al. Cognition and psychopathology in myoclonus-dystonia. J Neurol Neurosurg Psychiatry. 2012;83(8):814-20. doi:10.1136/jnnp-2011-301386
• 24 Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L et al. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology. 2012;79(11):1168-73. doi:10.1212/WNL.0b013e3182698d6c
• 25 Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord. 2010;25(4):459-65. doi:10.1002/mds.22983
• 26 Romano R, Bertolino A, Gigante A, Martino D, Livrea P, Defazio G. Impaired cognitive functions in adult-onset primary cranial cervical dystonia. Parkinsonism Relat Disord. 2014;20(2):162-5. doi:10.1016/j.parkreldis.2013.10.008
• 27 Newman JR, Boyle RS, O’Sullivan JD, Silburn PA, Mellick GD. Risk factors for idiopathic dystonia in Queensland, Australia. J Clin Neurosci. 2014;21(12):2145-9. doi:10.1016/j.jocn.2014.03.032
• 28 Molloy A, Kimmich O, Williams L, Butler JS, Byrne N, Molloy F et al. An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia. J Neurol Neurosurg Psychiatry. 2015;86(3):331-5. doi:10.1136/jnnp-2014-307699
• 29 Defazio G, Abbruzzese G, Girlanda P, Buccafusca M, Currà A, Marchese R et al. Primary cervical dystonia and scoliosis: a multicenter case control study. Neurology. 2003;60(6):1012-15. doi:10.1212/01.WNL.0000049932.22065.60
• 30 Hutchinson M. Sun exposure is an environmental factor for the development of blepharospasm. J Neurol Neurosurg Psychiatry. 2016;87(4):420-4. doi:10.1136/jnnp-2014-310266
• 31 Lin PT, Hallett M. The pathophysiology of focal hand dystonia. J Hand Ther. 2009;22(2):109-14. doi:10.1016/j.jht.2008.10.008
• 32 Leijnse JN, Hallett M. Etiological musculo-skeletal factor in focal dystonia in a musician’s hand: a case study of the right hand of a guitarist. Mov Disord. 2007;22:1803-8. doi:10.1002/mds.21636
• 33 Weise D, Schramm A, Stefan K, Wolters A, Reiners K, Naumann M et al. The two sides of associative plasticity in writer’s cramp. Brain. 2006;129(10):2709-21. doi:10.1093/brain/awl221
• 34 Quartarone A, Morgante F, Sant’angelo A, Rizzo V, Bagnato S, Terranova C et al. Abnormal plasticity of sensorimotor circuits extends beyond the affected body part in focal dystonia. J Neurol Neurosurg Psychiatry. 2008;79(9):985-90. doi:10.1136/jnnp.2007.121632
• 35 Lehéricy S, Tijssen MA, Vidailhet M, Kaji R, Meunier S. The anatomical basis of dystonia: current view using neuroimaging. Mov Dis. 2013;28(7):944-57. doi:10.1002/mds.25527
• 36 Camargos S, Cardoso F. New algorithm for the diagnosis of hereditary dystonia. Arq Neuropsiquiatr. 2012;70(9):715-7. doi:10.1590/S0004-282X2012000900013
• 37 Saunders-Pullman R, Raymond D, Senthil G, Kramer P, Ohmann E, Deligtisch A et al. Narrowing the DYT6 dystonia region and evidence for locus heterogeneity in the Amish-Mennonites. Am J Med Genet A. 2007;143A(18):2098-105. doi:10.1002/ajmg.a.31887
• 38 Gajos A, Piaskowski S, Sławek J, Ochudło S, Opala G, Łobińska A et al. Phenotype of the DYT1 mutation in the TOR1A gene in a Polish population of patients with dystonia. A preliminary report. Neurol Neurochir Pol. 2007;41(6):487-94.
• 39 Xiao J, Uitti RJ, Zhao Y, Vemula SR, Perlmutter JS, Wszolek ZK et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol. 2012;71(4):458-69. doi:10.1002/ana.23547
• 40 Fuchs T, Saunders-Pullman R, Masuho I, San Luciano M, Raymond D, Factor S et al. Mutations in GNAL cause primary torsion dystonia. Nature Genet. 2013;45(1):88-92. doi:10.1038/ng.2496
• 41 Zech M, Lam DD, Francescatto L, Schormair B, Salminen AV, Jochim A et al. Recessive mutations in the α3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia. Am J Hum Genet. 2015;96(6):883-93. doi:10.1016/j.ajhg.2015.04.010
• 42 Lohmann K, Wilcox RA, Winkler S, Ramirez A, Rakovic A, Park JS et al. Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol. 2013;73(4): 537-545. doi:10.1002/ana.23829
• 43 Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29(1):66-9. doi:10.1038/ng709
• 44 Kinugawa K, Vidailhet M, Clot F, Apartis E, Grabli D, Roze E. Myoclonus-dystonia: an update. Mov Disord. 2009;24(4):479-89. doi:10.1002/mds.22425
• 45 Mencacci NE, Rubio-Agusti I, Zdebik A, Asmus F, Ludtmann MH, Ryten M et al A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia. Am J Hum Genet. 2015;96(6):938-47. doi:10.1016/j.ajhg.2015.04.008
• 46 Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. 1994;8(3):236-42. doi:10.1038/ng1194-236
• 47 Lüdecke B, Dworniczak B, Bartholomé K. A point mutation in the tyrosine hydroxylase gene associated with Segawa’s syndrome. Hum Genet. 1995;95(1):123-5. doi:10.1007/BF00225091
• 48 Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology. 1991;41(2 Pt 1):174-81. doi:10.1212/WNL.41.2_Part_1.174
• 49 Camargos S, Scholz S, Simón-Sánchez J, Paisán-Ruiz C, Lewis P, Hernandez D et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol. 2008;7(3):207-15. doi:10.1016/S1474-4422(08)70022-X
• 50 Evidente VG, Advincula J, Esteban R, Pasco P, Alfon JA, Natividad FF et al. Phenomenology of “Lubag” or X-linked dystonia-parkinsonism. Mov Disord. 2002;17(6):1271-7. doi:10.1002/mds.10271
• 51 Aguiar PC, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M et al. Mutations in the Na(+)/K(+)-ATPase alpha-3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron. 2004;43(2):169-75. doi:10.1016/j.neuron.2004.06.028
• 52 Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, Maljevic S et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest . 2008;118(6):2157-68. doi:10.1172/JCI34438.
• 53 Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev. 2009;31(7):545-52. doi:10.1016/j.braindev.2009.02.008
• 54 Bhatia KP. The paroxysmal dyskinesias. J Neurol. 1999;246(3):149-55. doi:10.1007/s004150050325
• 55 Lee HY, Huang Y, Bruneau N, Roll P, Roberson ED, Hermann M et al. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Reports. 2012;1(1):2-12. doi:10.1016/j.celrep.2011.11.001
• 56 Bruno MK, Lee HY, Auburger GW, Friedman A, Nielsen JE, Lang AE et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology. 2007;68(21):1782-9. doi:10.1212/01.wnl.0000262029.91552.e0
• 57 Granata A, Schiavo G, Warner TT. TorsinA and dystonia: from nuclear envelope to synapse. J Neurochem. 2009;109(6):1596-109. doi:10.1111/j.1471-4159.2009.06095.x
• 58 Chen P, Burdette AJ, Porter JC, Ricketts JC, Fox SA, Nery FC et al. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Hum Mol Genet. 2010;19(18):3502-15. doi:10.1093/hmg/ddq266
• 59 Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci USA. 2004;101(3):847-52. doi:10.1073/pnas.0304375101
• 60 Granata A, Watson R, Collinson LM, Schiavo G, Warner TT. The dystonia-associated protein torsinA modulates synaptic vesicle recycling. J Biol Chem. 2008;283(12):7568-79. doi:10.1074/jbc.M704097200
• 61 Burdette AJ, Churchill PF, Caldwell GA, Caldwell KA. The early-onset torsion dystonia-associated protein, torsinA, displays molecular chaperone activity in vitro. Cell Stress Chaperones. 2010;15(5):605-17. doi:10.1007/s12192-010-0173-2
• 62 Nery FC, Zeng J, Niland BP, Hewett J, Farley J, Irimia D et al. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. J Cell Sci. 2008;121(20):3476-86. doi:10.1242/jcs.029454
• 63 Bragg DC, Armata IA, Nery FC, Breakefield XO, Sharma N. Molecular pathways in dystonia. Neurobiol Dis. 2011;42(2):136-47. doi:10.1016/j.nbd.2010.11.015
• 64 O’Farrell CA, Martin KL, Hutton M, Delatycki MB, Cookson MR, Lockhart PJ. Mutant torsinA interacts with tyrosine hydroxylase in cultured cells. Neuroscience. 2009;164(3):1127-37. doi:10.1016/j.neuroscience.2009.09.017
• 65 Konakova M, Huynh DP, Yong W, Pulst SM. Cellular distribution of torsin A and torsin B in normal human brain. Arch Neurol. 2001;58(6):921-7. doi:10.1001/archneur.58.6.921
• 66 Fuchs T, Gavarini S, Saunders-Pullman R, Raymond D, Ehrlich ME, Bressman SB et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet. 2009;41(3):286-8. doi:10.1038/ng.304
• 67 Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par4) to PML nuclear bodies. Oncogene. 2003;22(16):2432-42. doi:10.1038/sj.onc.1206271
• 68 Cayrol C, Lacroix C, Mathe C, Ecochard V, Ceribelli M, Loreau E et al. The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood. 2007;109(2):584-94. doi:10.1182/blood-2006-03-012013
• 69 Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, Goto S et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet. 2007;80(3);393-406. doi:10.1086/512129
• 70 Mazars R, Gonzalez-de-Peredo A, Cayrol C, Lavigne AC, Vogel JL, Ortega N et al. The THAP-zinc finger protein THAP1 associates with coactivator HCF-1 and O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias. J Biol Chem. 2010;285(18):13364-71. doi:10.1074/jbc.M109.072579
• 71 Grundmann K, Reischmann B, Vanhoutte G, Hübener J, Teismann P, Hauser TK et al. Overexpression of human wildtype type torsinA and human Delta GAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol Dis. 2007;27(2):190-206. doi:10.1016/j.nbd.2007.04.015
• 72 Zech M, Castrop F, Schormair B, Jochim A, Wieland T, Gross N et al. DYT16 revisited: exome sequencing identifies PRKRA mutations in a European dystonia family. Mov Disord. 2014;29(12):1504-10. doi:10.1002/mds.25981
• 73 Huang X, Hutchins B, Patel RC. The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR). Biochem J. 2002;366(1):175-86. doi:10.1042/bj20020204
• 74 Singh M, Castillo D, Patel CV, Patel RC. Stress-induced phosphorylation of PACT reduces its interaction with TRBP and leads to PKR activation. Biochemistry. 2011;50(21):4550-60. doi:10.1021/bi200104h
• 75 Vaughn LS, Bragg DC, Sharma N, Camargos S, Cardoso F, Patel RC. Altered activation of protein kinase PKR and enhanced apoptosis in dystonia cells carrying a mutation in PKR activator protein PACT. J Biol Chem. 2015;290(37):22543-57. doi:10.1074/jbc.M115.669408
• 76 Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001-12. doi:10.1002/mds.25552
• 77 Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11(1):41-7. doi:10.1002/ana.410110108
• 78 Lang AE, Sheehy MP, Marsden CD. Anticholinergics in adult-onset focal dystonia Can J Neurol Sci. 1982;9(3):313-9. doi:10.1017/S0317167100044139
• 79 Nutt JG, Hammerstad JP, Garmo P, Carter J. Cranial dystonia: double-blind crossover study of anticholinergics. Neurology. 1984;34(2):215-7. doi:10.1212/WNL.34.2.215
• 80 Quinn NP, Lang AE, Sheehy MP, Marsden CD. Lisuride in dystonia. Neurology. 1985;35(5):766-9. doi:10.1212/WNL.35.5.766
• 81 Nutt JG, Hammerstad JP, Carter JH, Garmo PL. Lisuride treatment of focal dystonias. Neurology. 1985;35(8):1242-3. doi:10.1212/WNL.35.8.1242
• 82 Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN et al. Dystonia: treatment with bromocriptine. Clin Neuropharmacol. 1985;8(4):328-33. doi:10.1097/00002826-198512000-00003
• 83 Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986;36(2):160-4. doi:10.1212/WNL.36.2.160
• 84 Carella F, Girotti F, Scigliano G, Caraceni T, Joder-Ohlenbusch AM, Schechter PJ. Double-blind study of oral gamma-vinyl GABA in the treatment of dystonia. Neurology. 1986;36(1):98-100. doi:10.1212/WNL.36.1.98
• 85 Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445-51 doi:10.1176/ajp.147.4.445
• 86 Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066-72. doi:10.1212/WNL.46.4.1066
• 87 Ransmayr G, Kleedorfer B, Dierckx RA, Poewe W, Kemmler GW, Gerstenbrand F. Pharmacological study in Meige’s syndrome with predominant blepharospasm. Clin Neuropharmacol. 1988;11(1):68-76. doi:10.1097/00002826-198802000-00007
• 88 Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. J Neurol Neurosurg Psychiatry. 1989 ;52(5):631-5. doi:10.1136/jnnp.52.5.631
• 89 Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil. 1999;80(1):13-9. doi:10.1016/S0003-9993(99)90301-5
• 90 Grañana N, Ferrea M, Scorticati MC, Díaz S, Arrebola M, Torres L et al. Beneficial effects of diphenhydramine in dystonia. Medicina (B Aires). 1999;59(1):38-42.
• 91 Rice J, Waugh MC. Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol. 2009;24(2):176-82. doi:10.1177/0883073808322668
• 92 Zadikoff C, Wadia PM, Miyasaki J, Chen R, Lang AE, So J et al. Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial. Basal Ganglia. 2011;1(2)91-5. doi:10.1016/j.baga.2011.04.002
• 93 Bonouvrié LA, Becher JG, Vles JS, Boeschoten K, Soudant D, Groot V et al. Intrathecal baclofen treatment in dystonic cerebral palsy: a randomized clinical trial: the IDYS trial. BMC Pediatr. 2013;13(1):175. doi:10.1186/1471-2431-13-175
• 94 Pozin I, Bdolah-Abram T, Ben-Pazi H. Levodopa does not improve function in individuals with dystonic cerebral palsy.J Child Neurol. 2014;29(4):534-7. doi:10.1177/0883073812473645
• 95 Maltese M, Martella G, Madeo G, Fagiolo I, Tassone A, Ponterio G et al. A Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1muscarinic receptors. Mov Dis. 2014;29(13):1655-65. doi:10.1002/mds.26009
• 96 Martella G, Maltese M, R, Schirinzi T, Madeo G, Sciamanna G al. Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. Neurobiol Dis. 2014;65:124-32. doi:10.1016/j.nbd.2014.01.016
• 97 Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol. 2004;11(6):361-70. doi:10.1111/j.1468-1331.2004.00845.x
• 98 Hallet M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114. doi:10.1016/j.toxicon.2012.12.004
• 99 Mundinger F. [New stereotactic treatment of spasmodic torticollis with a brain stimulation system]. Med Klin. 1977;72(46):1982-6. German.
• 100 Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology. 1999;53(4):871-4. doi:10.1212/WNL.53.4.871
• 101 Vidailhet M, Jutras MF, Grabli D, Roze E. Deep brain stimulation for dystonia. Neurol Neurosurg Psychiatry. 2013;84(9):1029-42. doi:10.1136/jnnp-2011-301714
• 102 Panov F, Gologorsky Y, Connors G, Tagliati M, Miravite J, Alterman RL. Deep brain stimulation in DYT1 dystonia: a 10-year experience. Neurosurgery. 2013;73(1):86-93. doi:10.1227/01.neu.0000429841.84083.c8
• 103 Cif L, Vasques X, Gonzalez V, Ravel P, Biolsi B, Collod-Beroud G et al. Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: An open-label study. Mov Disord. 2010;25(3):289-99. doi:10.1002/mds.22802
• 104 Sokal P, Rudaś M, Harat M, Szylberg Ł, Zieliński P. Deep anterior cerebellar stimulation reduces symptoms of secondary dystonia in patients with cerebral palsy treated due to spasticity. Clin Neurol Neurosurg. 2015;135:62-8. doi:10.1016/j.clineuro.2015.05.017
• 105 Schjerling L, Hjermind LE, Jespersen B, Madsen FF, Brennum J, Jensen SR et al.A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg. 2013;119(6):1537-45. doi:10.3171/2013.8.JNS13844
• 106 Mills KA, Markun LC, San Luciano M, Rizk R, Allen IE, Racine CA et al. Effect of subthalamic nucleus deep brain stimulation on dual-task cognitive and motor performance in isolated dystonia. J Neurol Neurosurg Psychiatry. 2015;86(4):404-9. doi:10.1136/jnnp-2014-307942